Article
From clinical trials to clinical practice: predictors of response to erlotinib in advanced non-small cell lung cancer patients pretreated with chemotherapy.
Tumori - 1 Jan 2000
Mazzoni Francesca, Rotella Virginia, Pratesi Nicola, Boni Luca, Simi Lisa, Orlando Claudio, Comin Camilla Eva, Maddau Cristina, Di Costanzo Francesco
Abstract excerpt
BACKGROUND: Inhibition of the epidermal growth factor receptor pathway with tyrosine kinase inhibitors can improve outcome of patients with advanced non-small cell lung cancer after first-line chemotherapy. The use of clinical characteristics and molecular markers may permit the identification of patients who are more likely to benefit from erlotinib. PATIENTS AND METHODS: Retrospective analysis of unselected...
Topics
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
- Antineoplastic Combined Chemotherapy Protocols
- Biomarkers, Tumor
- Carcinoma, Non-Small-Cell Lung
- Diarrhea
- Disease-Free Survival
- Drug Eruptions